亨廷顿病是今天神经科学中最好的投资
1Department of Biomedical Engineering, Tandon School of Engineering, New York University, New York City, NY, USA; Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA, USA.
Trends in molecular medicine
|February 14, 2026
概括
亨廷顿病 (HD) 虽然很罕见,但提供了一个独特的神经科学研究机会. 其明确的遗传学和可预测的进展使其成为最明确的途径,以推进大脑修复策略.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 神经系统疾病 神经系统疾病
背景情况:
- 亨廷顿病 (HD) 是一种罕见的,悲惨的,难以治愈的神经系统疾病.
- 尽管严重,但HD对科学研究具有独特的优势.
研究的目的:
- 突出亨廷顿病作为推进神经科学的战略入口点.
- 为了利用HD的独特特征开发大脑修复疗法.
主要方法:
- 对亨廷顿病遗传清晰度的分析.
- 在HD患者中评估可预测的疾病过程.
- 评估全球性HD社区的组织结构.
主要成果:
- 亨廷顿病具有特殊的遗传清晰度.
- 在HD的疾病进展是相对可预测的.
- 一个有组织的全球社区存在于HD研究和支持.
结论:
- 亨廷顿病的独特特征为大脑修复方面取得重大进展提供了最清晰的途径.
- HD研究可以作为理解和治疗其他复杂的神经疾病的模型.
相关概念视频
Parkinson's Disease: Overview
2.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.5K
Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Parkinson Disease ll: Pathophysiology
3
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
3
Huntington Disease l: Introduction
2
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
2


